Provided by Tiger Trade Technology Pte. Ltd.

Amneal Pharmaceuticals, Inc.

18.28
+0.20001.11%
Post-market: 18.280.00000.00%17:27 EDT
Volume:2.81M
Turnover:51.84M
Market Cap:5.83B
PE:38.02
High:19.18
Open:18.56
Low:18.12
Close:18.08
52wk High:19.26
52wk Low:9.49
Shares:319.00M
Float Shares:191.00M
Volume Ratio:1.31
T/O Rate:1.47%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.4808
EPS(LYR):0.2200
ROE:613.02%
ROA:8.60%
PB:176.58
PE(LYR):83.09

Loading ...

BRIEF-Amneal Pharmaceuticals Outlook FY Revenue USD 3,050-3,150 Million Vs. IBES Estimate USD 3,097 Million

Reuters
·
Apr 22

Amneal Pharma - Deal Expected to Deliver $400 Mln-$500 Mln in Financial Benefits

THOMSON REUTERS
·
Apr 22

Amneal Pharmaceuticals Outlook FY Adjusted Ebitda USD 740-770 Million

THOMSON REUTERS
·
Apr 22

Amneal Pharma - Expects Over 12 Commercial Biosimilars and 20 Pipeline Products by 2030

THOMSON REUTERS
·
Apr 22

Amneal Pharmaceuticals Inc FY2026 Shr View $0.99, REV View $3.10 Bln -- Lseg Ibes Data

THOMSON REUTERS
·
Apr 22

Amneal Pharmaceuticals Outlook FY Operating Cash Flow USD 350-400 Million

THOMSON REUTERS
·
Apr 22

Amneal Pharmaceuticals Outlook FY Revenue USD 3,050-3,150 Million VS. Ibes Estimate USD 3,097 Million

THOMSON REUTERS
·
Apr 22

Amneal Pharmaceuticals Outlook FY Capex USD 110 Million

THOMSON REUTERS
·
Apr 22

Amneal Pharma: Deal Expected to Provide Substantial Financial Synergies Through Elimination of Upcoming Milestone & Royalty Obligations Through 2030

THOMSON REUTERS
·
Apr 22

Amneal Pharma - Q1 2026 Preliminary Consolidated Net Revenue $723 Mln, up 4% Year Over Year

THOMSON REUTERS
·
Apr 22

Amneal Pharma - Raises 2026 Adj Diluted EPS Guidance to $0.95-$1.05

THOMSON REUTERS
·
Apr 22

Amneal Agrees to Acquire Kashiv Biosciences to Create Global Biosimilar Leader; Reports Strong Preliminary First Quarter 2026 Financial Results and Raises FY2026 Standalone Guidance

THOMSON REUTERS
·
Apr 22

Amneal says Phase 4 ELEVATE-PD interim data show CREXONT adds 3 hours “Good On” time

Reuters
·
Apr 20

Amneal Pharma - Interim Phase 4 Elevate-Pd Data Shows Clinically Meaningful Benefits of Crexont

THOMSON REUTERS
·
Apr 20

Amneal Pharma - Mean Daily Motor Fluctuations Decrease to 2.79 at Week 6 for Crexont

THOMSON REUTERS
·
Apr 20

Amneal Announces Additional Positive Interim Phase 4 Elevate-Pd Results With Crexont® for Parkinson’s Disease, Including Over 3 More Hours of Daily “Good on” Time When Switching From Rytary®

THOMSON REUTERS
·
Apr 20

Amneal Pharmaceuticals Initiated at Buy by UBS

Dow Jones
·
Apr 17

Amneal Pharmaceuticals Inc : UBS Initiates Coverage With Buy Rating and Target Price $19

THOMSON REUTERS
·
Apr 17

UBS Initiates Amneal Pharmaceuticals at Buy With $19 Price Target

MT Newswires Live
·
Apr 17

U.S. RESEARCH ROUNDUP-Adobe, Chevron, Exxon Mobil

Reuters
·
Apr 17